Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a biopharmaceutical company, enabled by a world-class generics business. For over 120 years, our commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients’ needs, now and in the future. We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world.
In the company’s own words · 10-K filed Feb 3, 2026 · SEC EDGAR
Business segments
Q2 2026 · $1.78BThe company’s own SEC segment disclosure.
- Austedo$676.0M38%
- Generics Medicians Including Otc And Biosimilars$660.0M37%
- Ajovy$116.0M7%
- Other Products$84.0M5%
- Uzedy$77.0M4%
- COPAXONE$61.0M3%
- Other (3)$103.0M6%
Teva Pharmaceutical Industries Limited (TEVA) reported revenue of $3.98B in Q1 2026 (quarter ended March 31, 2026), up 2.3% from the same quarter a year earlier. That came with a gross margin of 50% and net income of $369M (9.3% of revenue). For the full year FY2025, revenue was $17.3B (+4.3% year on year) and net income $1.41B. Its largest product in 2026-Q2 was Austedo at $676M, 38% of the disclosed total, just ahead of Generics Medicians Including Otc And Biosimilars at 37%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #15 of 28 by Smart Score